|Awarded On||February 18, 2015|
|Title||Vertical targeting of the B cell receptor in leukemia and lymphoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Ricardo Aguiar|
|Cancer Sites||Leukemia, Lymphoma|
Mature B cell tumors (non-Hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma) are associated with a poor outcome highlighting an unmet medical need for new therapies. These cancers are driven, in part, by the B cell receptor (BCR). We previously showed that downmodulation of the phosphodiesterase 4 (PDE4) can inhibit the BCR signals and reduce the growth of B cell cancers. These observations led us to open a clinical trial of Roflumilast (a FDA-approved PDE4 inhibitor) in patients with B cell lymphomas and leukemia. To date, five patients have been enrolled in the study and early signs of clinical benefit have already been observed. We now plan to build upon these early succe...